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Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most important 2 
causes of bacteremia. Recently, several epidemiological and microbiological changes have 3 
become evident in MRSA infections. The purposes of this study were to assess clinical 4 
characteristics of patients with MRSA bacteremia and microbiological changes in MRSA. 5 
We conducted a retrospective observational study on patients with MRSA bacteremia who 6 
were hospitalized between 2008 and 2011. We used univariate and multivariate analysis to 7 
evaluate the predictors associated with 30-day mortality. The 7-day and 30-day mortality 8 
rates were 12.0% and 25.3%, respectively. According to multivariate analysis, the 9 
independent predictors that associated with 30-day mortality were leukopenia, low serum 10 
albumin, high sequential organ failure assessment (SOFA) score, and quinolone use within 30 11 
days. Compared to previous data (2003–2007), the SOFA score of the new data set remained 12 
unchanged, but in-hospital mortality decreased significantly. In particular, the mortality 13 
associated with use of vancomycin (VCM) was significantly lower. Although the minimum 14 
inhibitory concentration of VCM required to inhibit the growth of 90% of organisms (MIC90) 15 
had not changed, the trough value of VCM changed significantly; a VCM trough value of 10 16 
or greater was significantly higher compared to previous data. Of the staphylococcal cassette 17 
chromosome mec (SCCmec) types, SCCmec II values decreased significantly, and SCCmec I 18 
and IV values increased significantly. Our results indicate that changes in VCM usage might 19 
contribute to decreased in-hospital mortality. 20 
 21 
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Staphylococcus aureus is one of the most important causes of bacteremia. In the 2 
United States, S. aureus is the second most common pathogenic cause of bacteremia [1]. In 3 
particular, methicillin-resistant S. aureus (MRSA) has been detected in 41% of S. aureus 4 
isolates, and the proportion of MRSA has increased from 22% in 1995 to 57% in 2001 [1]. 5 
The in-hospital mortality rate of S. aureus bacteremia is approximately 30–40% [2-4], and 6 
the 30-day mortality odds ratio of MRSA in comparison to methicillin-sensitive S. aureus 7 
(MSSA) is 2.15 [5]. 8 
Recently, several epidemiological and microbiological changes have become evident 9 
with regard to MRSA bacteremia. Community associated (CA)-MRSA strains, typically 10 
associated with staphylococcal cassette chromosome mec (SCCmec) types IV and V and 11 
often containing the Panton-Valentine leukocidin (pvl) gene, have become widespread in 12 
communities [6]; nosocomial infections with CA-MRSA strains also have increased in 13 
prevalence [7, 8]. Some reports have indicated that the minimum inhibitory concentration 14 
(MIC) of vancomycin (VCM) has increased (MIC creep) [9, 10]. Because of the increase in 15 
MIC, a VCM trough value of 10 mg/L or greater has been recommended to inhibit the 16 
development of antibiotic resistance [11].  17 
The purpose of this study was to assess clinical characteristics of patients with 18 
MRSA bacteremia. Furthermore, we aimed to determine and clarify the epidemiological and 19 
microbiological changes in patients with MRSA bacteremia by comparing data obtained in 20 
the current study (between 2008 and 2011) with data we had collected previously between 21 
2003 and 2007 [12], which had not exhibited increases in CA-MRSA nor MIC creep. 22 
23 
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Materials and methods 1 
Study design and patient population 2 
We conducted a retrospective observational study on patients with MRSA 3 
bacteremia who had been hospitalized at Nagasaki University Hospital between January 2008 4 
and December 2011. Patients who were less than 20 years of age were excluded from this 5 
study. For patients who developed MRSA bacteremia several times within a 4-year period, 6 
only the first episode of MRSA bacteremia was included in the data set. 7 
We investigated baseline characteristics, illness severity, presumed source, 8 
antimicrobial regimens, and outcomes. We also evaluated antimicrobial susceptibility, 9 
SCCmec types, and virulence genes in preserved strains. In addition, we compared 10 
non-survivors of MRSA bacteremia to survivors. Finally, we compared the present data set to 11 
data we had collected previously from individuals who MRSA bacteremia between January 12 
2003 and December 2007 [12].  13 
We adhered to the Japanese ethical guidelines for epidemiologic studies. The 14 
protocol for this study was approved by the ethics committees of Nagasaki University 15 
Hospital (No. 12062540). 16 
 17 
Definition of bacteremia 18 
 In this study, bacteremia was defined as confirmation of 1 or more positive blood 19 
cultures from patients exhibiting clinical signs of infection, such as fever, chills, and sweats. 20 
When the chief physician described in a medical record as a contamination of MRSA, the 21 
patient was excluded from this study. Bacteremia was presumed in patients who presented 22 
with typical symptoms and from whom MRSA was isolated prior to the onset of bacteremia. 23 
The infection was deemed catheter-related if inflammatory signs were observed at the 24 
catheter insertion point and if the catheter culture was MRSA positive. Patients were 25 
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diagnosed with MRSA pneumonia if they met the following criteria: (1) isolation of MRSA 1 
from sputum, bronchoalveolar lavage, or transthoracic aspiration prior to initial antimicrobial 2 
therapy; (2) chest radiographs that are consistent with pneumonia diagnosis; (3) symptoms or 3 
signs of pneumonia, such as cough, purulent sputum, abnormal auscultatory findings, signs of 4 
respiratory failure, and signs of dyspnea. MRSA bacteremia was classified as 5 
community-acquired, healthcare-associated, or hospital-acquired in accordance with the 6 
previous report [13].  7 
 8 
Assessment of laboratory data and illness severity 9 
In this study, we used vital data and laboratory data that were collected from the 10 
patient on the day the patient’s blood culture first yielded positive result. Leukopenia was 11 
defined as a white blood cell (WBC) count of less than 4,000 /µL. Illness severity was 12 
assessed by SOFA score [14]. 13 
 14 
Identification of bacteria 15 
All S. aureus isolates were identified by morphologic analysis of colonies, Gram 16 
stain, and the use of the Phoenix bacterial identification system (BD Diagnostics ; Sparks, 17 
MD, USA). Isolates were identified as MRSA if the oxacillin MIC was at least 4 µg/mL. The 18 
MICs of the preservation strains were measured using a dilution antimicrobial susceptibility 19 
test according to the manufacturer’s instructions (Eiken Chemical; Tokyo, Japan). The MICs 20 
of VCM, teicoplanin (TEIC), arbekacin (ABK), linezolid (LZD), and daptomycin (DAP) 21 
were determined after 24 hours of incubation at 35°C. 22 
 23 
Real-time PCR assay 24 
DNA extraction and real-time PCR were performed as reported previously [12, 15]. 25 
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Bacterial DNA was extracted using Chelex (Bio-Rad Laboratories; Hercules, CA, USA), 1 
methanol, and boiling methods. Real-time PCR was performed using a LightCycler 480 2 
(Roche Applied Science; Mannheim, Germany) to amplify a total of 10 genes in the same run. 3 
Primers and probes were purchased from Nihon Gene Research Laboratories Inc. (Miyagi, 4 
Japan). 5 
 6 
Data collection 2003–2007 7 
The data collected between 2003 and 2007 was reported previously [12]. In this 8 
study, we compared our newly obtained data (2008–2011) with our previously obtained data 9 
(2003–2007) to confirm changes in patients with MRSA bacteremia. The previous report did 10 
not include VCM trough values and mortality rates in relation to initial antimicrobial therapy; 11 
those values were derived newly from the 2003–2007 database. 12 
  13 
Statistical analysis  14 
A statistical software package (StatMate IV for Windows®; ATMS Co., Ltd.; Tokyo, 15 
Japan) was used to perform statistical comparisons. All comparisons were unpaired and tests 16 
of significance were two-tailed. The α-level denoting statistical significance was set to 0.05 17 
or less. Continuous variables were compared using the Student t-test if the variables were 18 
distributed normally or the Mann-Whitney U-test if the variables exhibited non-normal 19 
distribution. The chi-square or Fisher’s exact test was used to compare categorical variables. 20 
Variables with a P value less than 0.20 according to univariate analysis were considered for 21 
inclusion in the forward stepwise multivariate logistic regression analysis to determine the 22 
predictors associated with 30-day mortality. The contribution of each potential risk factor was 23 
denoted by the odds ratio (OR) and associated 95% confidence interval (CI). 24 
 25 
26 




Patient characteristics 2 
During the study period, we evaluated 83 patients (58 men and 25 women) with 3 
MRSA bacteremia comprised of 3 patients with community-acquired bacteremia, 5 patients 4 
with healthcare-associated bacteremia, and 75 patients with hospital-acquired bacteremia. 5 
Patient characteristics are listed in Table 1. The mean age and body temperature of patients 6 
were 67.3 years and 38.8°C, respectively. The severity of MRSA bacteremia was determined 7 
based on the mean SOFA score, which was 5.8. A SOFA score of 5 or greater was assigned 8 
to 43 (51.8%) patients 9 
A total of 34 (41.0%) patients had a malignancy, but only 8 of those patients had 10 
received chemotherapy within 30 days. Of the 83 patients, 33 (39.8%) had cardiovascular 11 
disease, 24 (28.9%) had diabetes mellitus, 20 (24.1%) had chronic renal failure, and 18 12 
(21.7%) had a disease of the central nerve system. In contrast, only 10 patients (12.0%) had 13 
received immunosuppressive drugs or corticosteroids and 5 patients (6.0%) had a history of 14 
transplantation. The presumed sources of infection in patients with MRSA bacteremia are 15 
listed in Table 2. The most frequent source of bacteremia was intravascular devices (25 16 
patients, 30.1%) followed by the respiratory tract (17 patients, 20.5%). In addition, the use of 17 
antimicrobial agents during the previous 30 days also was investigated (Table 3); 18 
carbapenems were used most frequency followed by penicillin. Anti-MRSA agents had been 19 
used by 12 (14.5%) of the patients with MRSA bacteremia. 20 
 21 
Antimicrobial regimens and MICs 22 
Initial patient antimicrobial regimens and MIC curves are shown in Fig. 1. Some 23 
patients were treated with VCM (37 [44.6%]), TEIC (11 [13.3%], or LZD 18 (18 [21.7%]). 24 
One patient was treated with VCM and ABK. In addition, 16 (19.4%) were treated with no 25 
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anti-MRSA agents. Since use of DAP was started at 2011 in Japan, there was no patient who 1 
was treated with DAP. The MICs of the 78 isolates were measured. The MIC90 values for 2 
VCM, TEIC, ABK, LZD, and DAP were 1, 1.5, 0.75, 4, and 0.75, respectively. Most strains 3 
obtained from blood cultures were sensitive to these 5 antimicrobial agents, and VCM MIC 4 
creep was not observed. 5 
 6 
Genetic analysis 7 
The SCCmec and virulence genes were identified in this study. Of the 78 patients, 18 8 
(23.1%) carried SCCmec type I, 35 (44.9%) carried SCCmec type II, 1 (1.3%) carried 9 
SCCmec type III, and 24 (30.8%) carried SCCmec type IV. With regard to virulence genes, 10 
41 patient isolates (52.6%) tested positive for tsst, 38 patient isolates (48.7%) were sec 11 
positive, and none of the isolates tested positive for either etb or pvl. Of the 35 patient 12 
SCCmec type II isolates, 28 (80.0%) were positive for tsst and sec genes, as were 33.3% 13 
(8/24) of the SCCmec type IV isolates. None of the SCCmec type I isolates tested positive for 14 
tsst or sec. The prevalence of tsst and sec in SCCmec type II isolates was significantly higher 15 
that the prevalence of these genes in SCCmec types I and IV (P < 0.001). 16 
 17 
Outcomes and prognostic factors 18 
The 7-, 30-day, and in-hospital mortality rates were 12.0%, 18.1%, and 25.3%, 19 
respectively. Predictors associated with 30-day mortality based on univariate and multivariate 20 
analysis are shown in Table 4. The univariate analysis included patient characteristics 21 
(including vital signs and laboratory data), presumed source of infection, initial antimicrobial 22 
regimen, antimicrobial agents that were used within the previous 30 days, MICs of 23 
anti-MRSA agents, SCCmec types, and virulence genes. This analysis determined that 24 
predictors associated with 30-day mortality include hematologic malignancy, respiratory 25 
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disease, hepatobiliary disease, leukopenia, low serum albumin (≤2.5 g/dL), and high SOFA 1 
scores (≥5 and ≥15). Based on multivariate analysis, the independent predictors associated 2 
with 30-day mortality were leukopenia (OR, 31.5; 95% CI, 3.1–322.8; P = 0.004), low serum 3 
albumin (≤2.5 g/dL) (OR, 14.7; 95% CI, 1.9–116.2; P = 0.011), high SOFA score (≥15) (OR, 4 
38.6; 95% CI, 3.5–431.1; P = 0.011), and use of quinolones within the previous 30 days (OR, 5 
6.2; 95% CI, 1.0–38.9; P = 0.050).  6 
 7 
Comparison to 2003–2007 data 8 
To confirm the changes that have developed in MRSA bacteremia, we compared 9 
data from this study with data gathered between 2003 and 2007, which we had reported 10 
previously [12]. Compared to the previous study, the proportion of male patients was 11 
significantly higher and the proportion who received immunosuppressive drugs or 12 
corticosteroids was significantly lower in this study (53.0% versus 69.9%; P = 0.026 and 13 
30.1% versus 12.0%; P = 0.004, respectively). No significant differences were evident 14 
between the 2 studies with regard to presumed sources of infection; however, although the 15 
proportion of intravascular devices used was higher in this study, the differences were not 16 
significant. With regard to SOFA scores, the 2 studies did not differ significantly (6.0 ± 4.5 17 
versus 5.8 ± 4.7; P = 0.739). However, the in-hospital mortality rate from this study was 18 
significantly lower than in the previous study (39.8% versus 25.3%; P = 0.047).  19 
A comparison of the initial antimicrobial regimens and mortality rates based on the 20 
initial antimicrobial agents is shown in Table 5. The frequency of VCM use was significantly 21 
greater in this study compared to the previous study (26.5% versus 44.6%; P = 0.015). In 22 
contrast, the frequency of TEIC use was significantly lower in this study (39.8% versus 23 
13.3%; P < 0.001). In addition, the rate of mortality based on VCM use was significantly 24 
lower in this study (59.1% versus 21.6%; P = 0.004). Whereas no changes were observed in 25 
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the VCM MIC90 between the 2 studies (Table 5), a change was observed in the VCM trough 1 
value in patients who received VCM. In this study, the VCM trough value was measured in 2 
59.5% of the patients who had received VCM (22/37); the prevalence of values ≥ 10 was 3 
significantly higher compared to the previous study (50.0% versus 76.0%; P = 0.031).  4 
With regard to SCCmec types, the prevalence of type II was significantly lower in 5 
this study compared with the previous study (79.2% versus 44.9%; P < 0.001). In contrast, 6 
the prevalence of SCCmec types I and IV were higher (2.6% versus 23.1%; P < 0.001, and 7 
18.2% versus 30.8%; P = 0.069) (Fig. 2). The prevalence of tsst and sec genes was 8 
significantly lower in this study (79.2% versus 52.6%; P < 0.001 and 76.6% versus 48.7%; P 9 
< 0.001, respectively) (Fig. 2). The mortality rates based on SCCmec types and virulence 10 
genes could not be compared between the 2 studies because these data were not available 11 
from the previous study. In this study, the 30-day mortality rates for SCCmec types I, II, and 12 
IV were 11.1%, 22.9%, and 16.7%, respectively. In addition, the 30-day mortality rates based 13 
on the presence or absence of virulence genes were 17.0% and 19.0%, respectively. No 14 
significant differences were evident in 30-day mortality based on SCCmec types and 15 
virulence genes. 16 
17 




Our results revealed clinical characteristics of patients with MRSA bacteremia and 2 
microbiological changes in MRSA. Compared to our previous study [12], several changes in 3 
initial antibiotic regimens, SCCmec types, and virulence genes had emerged. In contrast, 4 
patient characteristics, severity of illness, and MICs did not change significantly. 5 
Additionally, in-hospital mortality was significantly decreased in this study compared to the 6 
previous study. 7 
With regard to initial antibiotic regimens, the frequency of VCM use had increased 8 
significantly and the VCM-based mortality had decreased significantly in this study. Because 9 
other antimicrobial agents were not associated with changes in mortality, the changed 10 
frequency of VCM use appeared important for decreased mortality. Although the MIC90 for 11 
VCM had not changed between the 2 studies, the trough value of VCM had changed 12 
significantly; the prevalence of patients in this study with a VCM trough value of 10 or 13 
greater was significantly higher in this study. In some studies, a VCM trough value less than 14 
10 mg/L may have served as a predictor of therapeutic failure and introduced the possibility 15 
that VCM-resistant MRSA would emerge [16, 17]. A VCM trough value of 10 mg/L or 16 
greater has been recommended in a consensus review on therapeutic VCM monitoring [11]. 17 
Therefore, change VCM usage of VCM may contribute to decreasing in-hospital mortality. 18 
For SCCmec types, type II prevalence was significantly lower, and type I and IV 19 
prevalence were higher in this study. Worldwide, SCCmec type IV, which usually associates 20 
with CA-MRSA, has been observed widely—in community-based infections and also in 21 
nosocomial infections [7, 8]. In Japan, the historical prevalence of SCCmec type IV was 22 
approximately 4% in previous studies [18, 19] and has grown to 20.0% according to a recent, 23 
nationwide Japanese survey on MRSA [19]. Increases in SCCmec type IV occur commonly 24 
in Japan and other countries, but exhibit differences among clones. In the United States and 25 
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Europe, the most common strain has been the USA300 strain, which carries the pvl gene and 1 
is the most common CA-MRSA clone. In contrast, the prevalence of the pvl gene in 2 
CA-MRSA was approximately 2% to 4% in Japan [20, 21]. Thus, most CA-MRSA strains in 3 
Japan were not derived from the USA300 strain. In our study, none of the strains carried the 4 
pvl gene, and it is similar to precious studies in Japan [20, 21]. In addition, SCCmec type I 5 
also exhibited a significant increase in this study. However, no similar studies have been 6 
conducted. Accordingly, further investigation is needed to reveal whether SCCmec type I 7 
increases temporarily. 8 
The question that followed was whether these changes in SCCmec type contributed 9 
to decreased in-hospital mortality. In the previous study, the 90-day cumulative probability of 10 
survival in patients with MSSA, CA-MRSA, or hospital-associated (HA)-MRSA bacteremia 11 
were 71%, 70%, and 55%, respectively; the only association with an increased risk of 12 
mortality according to multivariate analysis was observed in patients with HA-MRSA 13 
bacteremia in comparison to patients with MSSA bacteremia [22]. Other study showed that 14 
the 30-day cumulative survival rate for patients with SCCmec types II or IV were 60.0% and 15 
81.8%, respectively [23]. In our study, the 30-day mortality of patients with SCCmec type IV 16 
was lower than that of patients with SCCmec type II, and the 30-day mortality of patients 17 
with SCCmec type I also was lower than that of patients with SCCmec type II. However, the 18 
difference was not significant. Therefore, we could not decide whether the changes in 19 
SCCmec type contributed to decreased in-hospital mortality. In addition, the changing 20 
prevalence of virulence genes did not appear to contribute to decreased in-hospital mortality; 21 
the 30-day mortality rate did not change with the presence or absence of virulence genes 22 
(17.0% and 19.0%, respectively). It is certain that the prevalence of virulence genes tsst and 23 
sec was significantly lower in this study than in our previous study. However, the changed 24 
prevalence may be related to changed SCCmec types. In this study, the prevalence of tsst and 25 
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sec genes in SCCmec types I and IV was significantly lower than the prevalence of these 1 
genes in SCCmec type II. Consequently, the decreased prevalence of SCCmec type II led to 2 
the decreased prevalence of virulence genes.  3 
In contrast, changes in patient characteristics appear to contribute to decreased 4 
in-hospital mortality. Although nearly no changes were observed in patient characteristics in 5 
this study, the proportion of patients who received immunosuppressive drugs or 6 
corticosteroids was significantly lower than that in the previous study. The use of 7 
immunosuppressive drugs or corticosteroids had served as a predictor of in-hospital mortality 8 
based on univariate analysis in our previous study, and thus, the lower proportion of patients 9 
on these drugs in this study may have contributed to decreased in-hospital mortality. 10 
Additionally, transplantation was a predictor associated with mortality based on multivariate 11 
analysis in our previous study but not in this study. Although we are unable to provide an 12 
apparent explanation for why these patients decreased in this study, we have realized that 13 
infection prevention in the immunocompromised host might be effective in our hospital. In 14 
our hospital, Infection Control and Education Center was established at 2006, and 15 
multidrug-resistant Pseudomonas aeruginosa infection decreased after the establishment 16 
(data were not shown). Since a previous study reported that received infection control team 17 
consultation reduced the mortality of patients with MRSA bacteremia [24], there was some 18 
possibility that improvement of infection prevention in the immunocompromised host 19 
decreased in-hospital mortality. In comparison with our previous report, use of quinolones 20 
within the previous 30 days was the independent predictors associated with 30-day mortality. 21 
Quinolones were usually used at combination therapy in critically ill patients, but we could 22 
not clarify the causation of quinolones and in-hospital mortality. 23 
In conclusion, this study revealed that changes in VCM usage might contribute to 24 
decreased in-hospital mortality. Recently, many studies have been conducted on the 25 
Kaku et al. 14 / 16 
 
 
epidemiological and microbiological changes that have developed in MRSA bacteremia, but 1 
few of these studies have examined how changes affect in-hospital mortality. Therefore, 2 
further investigation is needed to clarify the influence that these changes have on outcomes. 3 
4 
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Fig. 2. A comparison of SCCmec types and virulence genes detected during 2 time frames, 2003–2007 and 2008–2011.























































*  P < 0.001
** P = 0.069
Table 1. Patient characteristics of patients with MRSA bacteremia 
 Sex (male/female)  58/25 
  Mean age (years)* 67.3 ± 17.0 
 Classification by the onset place of bacteremia: 
    Community-acquired 3 (3.6%) 
    Healthcare-associated 5 (6.0%) 
    Hospital-acquired 75 (90.4%) 
 Underlying disease: 
    Malignancy 34 (41.0%) 
      Hematologic malignancy 6 (7.2%) 
      Chemotherapy within 30 days 8 (9.6%) 
    Cardiovascular disease 33 (39.8%) 
    Diabetes mellitus 24 (28.9%) 
    Chronic renal failure 20 (24.1%) 
      Hemodialysis 17 (20.5%) 
    Central nurve system disease 18 (21.7%) 
    Respiratory disease 13 (15.7%) 
    Hepatobiliary disease 13 (15.7%) 
    Autoimmune/allergic disease 12 (14.5%) 
    Immunosupressive drugs or corticosteroids use 10 (12.0%) 
    Physical trauma 9 (10.8%) 
    Gastrointestinal disease 7 (8.4%) 
    Tlansplantation 5 (6.0%) 
  Body temprature (˚C) * 38.7 ± 4.7 
  SOFA-scorea* 5.8 ± 4.7 
    SOFA-score ≥ 5 43 (51.8%) 
  *Values are presented as means ± standard deviations.  
 
 
Table 2. Presumed source of infection in patients with MRSA bacteremia 
Presumed source Number of patients (%) 
 Intravascular device 25 (30.1%) 
 Respiratory tract (patients with pneumonia) 17 (20.5%) 
 Soft tissue 7 (8.4%) 
 Surgical wound 6 (7.2%) 
 Abdominal cavity 4 (4.8%) 
 Bone 2 (2.4%) 
 Others 5 (6.0%) 
 Unknown 17 (20.5%) 
 
 
Table 3. Antimircrobial agents used within last 30 days  
Antimicrobial agents* Number of patients (%) 
  Penicillins 21 (25.3%) 
  1st cefems 16 (19.3%) 
  2nd cefems 5 (6.0%) 
  3rd cefems 14 (16.9%) 
  Carbapenems 27 (32.5%) 
  Quinolones 14 (16.9%) 
  Anti-MRSA agents 12 (14.5%) 
    VCM 6 (7.2%) 
    TEIC 4 (4.8%) 
    ABK 1 (1.2%) 
    LZD 1 (1.2%) 
  Others 12 (14.5%) 
  All 63 (75.9%) 
  *There are some overlapping cases. 
 
 
Table 4. Univariate and multivariate analysis of predictors associated with 
30-day mortality of patients with bacteremia 
Predictor  OR  (95%CI) P value 
 Univariate analysis 
   Community-acquired bacteremia 10.3 (0.9 - 122.2) 0.143 
   Hematologic malignancy 12 (2.0 - 73.6) 0.008 
   Respiratory disease 5.8 (1.6 - 21.2) 0.013 
   Hepatobiliary disease  5.8 (1.6 - 21.2) 0.013 
   History of transplantation 8.3 (1.2 - 54.7) 0.056 
   Body temperature < 36.0 ˚C 10.3 (0.9 - 122.2) 0.143 
   Body temperature ≥ 39.0 ˚C, < 40.0 ˚C 2.9 (0.9 - 9.3) 0.111 
   Leukopenia 8 (1.8 - 34.9) 0.008 
   serum albumin ≤ 2.0 g/dl 10.3 (0.9 - 122.2) 0.143 
   serum albumin ≤ 2.5 g/dl 5.8 (1.6 - 20.1) 0.008 
   serum albumin ≤ 3.0 g/dl 7.6 (0.9 - 61.7) 0.061 
   SOFA-score ≥ 5 4.8 (1.2 - 18.5) 0.033 
   SOFA-score ≥ 10 4.4 (1.1 - 16.4) 0.059 
   SOFA-score ≥ 15 12 (2.0 - 73.6) 0.008 
   Use of carbapenem within last 30 days 2.9 (0.9 - 9.2) 0.111 
   Use of quinolones within last 30 days 3.3 (0.9 - 11.8) 0.133 
   Use of lincomycin within last 30 days 4.6 (1.1 - 19.7) 0.086 
 
 Multivariate analysis* 
    Leukopenia 31.5 (3.1 - 322.8) 0.004 
    serum albumin ≤ 2.5 g/dl 14.7 (1.9 - 116.2) 0.011 
    SOFA-score ≥ 15      38.6 (3.5 - 431.1) 0.003 
    Use of quinolones within last 30 days 6.2 (1.0-38.9) 0.050 




Table 5. Comparison of initial antimicrobial regimens, mortality, and MIC90 
between 2003 - 2007 and 2008 - 2011  
Antimicrobial agents 
No. of patients (%) 
P value 
2003-07 (n=83) 2008-11 (n=83) 
Initial antimicrobial regimens    
   
  VCM 22 (26.5%) 37 (44.6%) 0.015 
  TEIC 33 (39.8%) 11 (13.3%) < 0.001 
  ABK 3 (3.6%) 0 (0.0%) 0.244 
  LZD 11 (13.3%) 18 (21.7%) 0.152 
  VCM + ABK 0 (0.0%) 1 (1.2%) 0.316 
  No use of anti-MRSA agents 14 (16.9%) 16 (19.3%) 0.687 
Mortality according to initial antimicrobial agents 
  
  VCM 13/22 (59.1%) 8/37 (21.6%) 0.004 
  TEIC 11/33 (33.3%) 3/11 (27.3%) 0.709 
  LZD 3/11 (27.2%) 5/18 (27.8%) 0.690 
  No use of anti-MRSA agents 6/14 (42.9%) 5/16 (31.3%) 0.699 
MIC90* 
     
















*The number of strains that were used to measure MIC90 was 77 in 2003-07 and 78 in 2008-11 
 
